Patrys Limited · ASX:PAB

Patrys — Investor Presentation (November 2022)

27 slides from Patrys's investor presentation, Nov 24, 2022

  1. Slide 1: Investor Presentation

    Investor Presentation 24 November 2022

  2. Slide 2: Safe harbour statement

    Safe harbour statement The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of loss of capital invested

  3. Slide 3: Investment summary

    Investment summary Patrys’ deoxymab technology platform provides new ways for using antibodies to treat cancer: • Block repair of damaged DNA • Cross the blood brain barrier • Can be used alone or in combination with other therapies Deoxymab antibodies can be used as targeting agents for the deliver

  4. Slide 4: Company snapshot

    Company snapshot 12 month share price performance Shares 2.1B Market cap¹ A$41M Cash² A$7.2M HQ Melbourne Charmaine Gittleson (Chair) James Campbell (CEO & MD) Board Pamela Klein (NED) Suzy Jones (NED) Mike Stork (NED) Price¹ $0.020 12 mth high - low $0.045 - $0.018 Dr Dax Marcus Calder – 11.2% Subs

  5. Slide 5: Board of Directors

    Board of Directors Dr Charmaine Gittleson Dr Pamela M. Klein • Former Chief Medical Officer of CSL Limited • Former VP, Development at Genentech • Global expertise in drug development, • Board member of Argenx (Euronext & Nasdaq: ARGX) clinical development, regulatory strategy • Former CMO of Intell

  6. Slide 6: Technology Overview

    Technology Overview

  7. Slide 7: Novel anti-cancer therapeutic antibody

    Novel anti-cancer therapeutic antibody Deoxymabs bind to DNA and have a unique combination of properties: • Cancer seeking: tumours release DNA which attracts deoxymabs • Cell penetrating: able to get into cells and the cell nucleus • Block DNA damage repair (DDR): stops cancer cells replicating • C

  8. Slide 8: Deoxymabs: multiple therapeutic approaches

    Deoxymabs: multiple therapeutic approaches Single Agent Combination Therapies Targeted Therapies • Many cancers have pre-existing defects • Radiation therapy and many chemo • Antibody drug conjugates to in their DNA damage repair (DDR) drugs work by causing damage to DNA target payloads to cancer ce

  9. Slide 9: Deoxymab Results

    Deoxymab Results

  10. Slide 10: Improves survival in primary brain cancer

    Improves survival in primary brain cancer Mice with human GBM • Glioblastoma (GBM) is the most common primary brain cancer (23,000 new cases in the US pa) • GBM is highly aggressive with few effective treatment options (5- year survival rate = 5.6%) • Standard of Care for GBM is surgical removal of

  11. Slide 11: Improves effectiveness of radiation

    Improves effectiveness of radiation • Radiation is the standard of care for GBM patients Mice with high-grade glioma • Dose of radiation is limited by its side-effects • Combining with PAT-DX1 reduces the ability of cancer cells to repair DNA damage caused by radiation • ~25% improvement in median s

  12. Slide 12: Effective against brain metastases

    Effective against brain metastases • ~ 200,000 new cases of brain metastases (secondary brain Breast Cancer Brain Metastases cancer) in the US each year • The primary cancers that most often spread to the brain are cancers of the lung, breast, skin, colon, kidney and thyroid • Median survival ranges

  13. Slide 13: PAT-DX1 potential use in pancreatic cancer

    PAT-DX1 potential use in pancreatic cancer • Pancreatic cancer is one of the most common and aggressive Pancreatic Cancer Model cancer types, with a 5-year survival rate of 2–9% • Globally, 460,000 new cases and 432,000 deaths in 2018 • Limited treatment options • Second leading cause of cancer deat

  14. Slide 14: PAT-DX3 can target cancer drugs to tumours

    PAT-DX3 can target cancer drugs to tumours Breast Cancer Model • Antibody drug conjugates (ADCs) provide additional clinical benefits to antibodies alone • Proof of principle study with PAT-DX3 conjugated to MMAE (toxic anti-cancer drug used in approved ADCs) • Clear tumour-targeting effect when com

  15. Slide 15: Recent Developments

    Recent Developments

  16. Slide 16: Increasingly accessing non-dilutive funding

    Increasingly accessing non-dilutive funding $250k from inaugural Clinical Accelerator from Cure Brain Cancer Foundation • Deoxymab preclinical research at The Telethon Kids Institute - led by Professor Terrance Johns o in vitro and in vivo models of high-grade glioma o combining deoxymabs with stand

  17. Slide 17: New discoveries and patent applications filed

    New discoveries and patent applications filed Neutrophil extracellular traps (NETs) • Peer-reviewed publication reported that PAT-DX1 suppresses the formation of NETs • NETs are implicated in progression and metastasis in some cancers • Offers mechanistic rationale to the previously-described abilit

  18. Slide 18: Looking Ahead

    Looking Ahead

  19. Slide 19: PAT-DX1 clinical trial preparation for H2 2023

    PAT-DX1 clinical trial preparation for H2 2023 • Cell line for manufacturing selected in 2021 • Engineering run successfully completed in July 2022 • No major concerns identified in non-GLP toxicology in rodents and NHPs • GLP toxicology studies (rodents, NHPs) have commenced • Planning well underwa

  20. Slide 20: PAT-DX3 development path

    PAT-DX3 development path • PAT-DX3 is differentiated from PAT-DX1 o Different pharmacokinetic profile o Crosses the blood brain barrier independent of cancer in the brain o Efficacy in animal models • Potential for use as a targeting agent (more conjugation sites than PAT-DX1) o 99.7% tumour growth

  21. Slide 21: Development timeline

    Development timeline 4Q 1Q 2Q 3Q 4Q 1Q 2Q Production GMP production and formulation PAT-DX1 Pre-clinical GLP toxicology Prepare & file Clinical Phase 1 Aust-HREA (IND) Pre-production Master Cell Bank Downstream Engineering PAT-DX3 Production development run GLP toxicology Pre-clinical Platform expan

  22. Slide 22: Commercial Landscape

    Commercial Landscape

  23. Slide 23: Biologics typically transact earlier and at higher valuations than small molecules

    Biologics typically transact earlier and at higher valuations than small molecules The value of Patrys’ novel therapy is underpinned by potential for multiple applications to achieve better patient outcomes Source: GlobalData 1.Small molecules and biologics transactions between 2017 and 2019 2.Deal

  24. Slide 24: Relevant recent pre-clinical transactions

    Relevant recent pre-clinical transactions 24

  25. Slide 25: Deal landscape - recent example

    Deal landscape - recent example November 1, 2022 • Exelixis (NASDAQ, US$5.3B) and Cybrexa Therapeutics (US, private) establish exclusive collaboration giving Exelixis the Right to Acquire CBX- 12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan • US$60 million up front, total potential

  26. Slide 26: Why Patrys? Why now?

    Why Patrys? Why now? Patrys’ deoxymab antibodies have a novel target and mechanism, and are effective in animal models of multiple cancer types Deoxymabs target indications with significant unmet medical – including triple negative breast cancer, primary and secondary brain cancers First deoxymab, P

  27. Slide 27: Contact

    Contact Dr. James Campbell CEO and MD +61 3 9670 3273 info@patrys.com patrys.com Patrys Limited (ASX:PAB)

Patrys — Investor Presentation (November 2022) on 6ix